Therapeutic Applications

Beovu is a prescription medication used to treat specific chronic eye conditions that affect the macula, the part of the retina responsible for sharp, central vision. It belongs to a class of drugs known as anti-vascular endothelial growth factor (anti-VEGF) agents.

Neovascular (Wet) Age-Related Macular Degeneration

The primary use of Beovu is the treatment of neovascular age-related macular degeneration (nAMD), commonly referred to as wet AMD. This condition occurs when abnormal blood vessels grow underneath the retina. These vessels are fragile and often leak fluid and blood, which can lead to swelling and damage to the macula. If left untreated, this process can cause rapid and severe loss of central vision.

Diabetic Macular Edema

Beovu is also used to treat diabetic macular edema (DME). This condition is a complication of diabetes where high blood sugar levels damage the small blood vessels in the retina. This damage leads to fluid leakage and accumulation in the macula, causing it to swell. The resulting edema can blur vision and make it difficult to perform daily tasks like reading or driving.

Mechanisms and Clinical Benefits

The active ingredient in Beovu, brolucizumab, works by targeting and inhibiting a specific protein called vascular endothelial growth factor (VEGF). In patients with wet AMD or DME, the body produces excessive amounts of this protein, which stimulates the growth of abnormal blood vessels and increases vascular permeability.

Reduction of Retinal Fluid

By blocking the action of VEGF, the medication helps to:

• Reduce leakage: It stabilizes existing blood vessels to prevent further fluid from entering the retinal layers.
• Decrease thickness: It aids in the resolution of existing edema, helping to return the central retina to a more normal thickness.
• Inhibit vessel growth: It slows or stops the formation of new, abnormal blood vessels that characterize wet AMD.

Impact on Vision

The goal of treatment is to stabilize or improve visual acuity. For many patients, the reduction in retinal fluid can lead to a clearing of central vision or a prevention of further vision loss. The therapeutic benefit is centered on maintaining the integrity of the macula to preserve the ability to see fine detail.

Eligibility Map: Who can and cannot use Beovu (Brolucizumab) — Official Regulatory Information

The eligibility for Beovu is strictly defined by official regulatory labeling, outlining specific populations who are allowed to use the medicine and those who are absolutely excluded.

---

Contraindications and Non-Eligibility

Classification	Population/Condition
Absolute Contraindication	Patients with active or suspected ocular or periocular infections.
Absolute Contraindication	Patients with active intraocular inflammation.
Absolute Contraindication	Patients with known hypersensitivity to brolucizumab or any excipients.
Use Not Established	Children and adolescents (under 18 years of age).

---

Conditional Eligibility and Restrictions

Beovu is indicated for use exclusively in adults (18 years and older). Use is not recommended during pregnancy or lactation. Women of childbearing potential must use effective contraception during treatment and for at least one month after the final dose. No dosage adjustment is required for patients with renal impairment or hepatic impairment, although studies in the hepatic population are limited. The medicine should not be administered to patients whose intraocular pressure is ge 30 mmHg.

Interactions with other medicines and products — Official Regulatory Information

This section describes the officially documented interaction profile for Brolucizumab, based strictly on government regulatory documents.

Interaction scope	Official Regulatory Statement
Medicinal product categories with documented interactions	Anti-VEGF medicinal products (ocular and systemic).
Specific interacting medicines (if explicitly listed)	No specific drug names are formally listed for metabolic or systemic pharmacokinetic interactions.
Mechanistic basis of interactions (only if stated in label)	Brolucizumab is a therapeutic protein and is not metabolized by cytochrome P450 (CYP) enzymes; therefore, CYP-mediated interactions are unlikely.
Timing-based interaction rules (if applicable)	Brolucizumab must not be administered concurrently with other anti-VEGF medicinal products (systemic or ocular).
Population-specific interaction notes (if applicable)	Renal or Hepatic Impairment: No dosage adjustment is necessary for patients with mild or moderate renal or hepatic impairment.
Interaction-related restrictions	Co-administration with any other anti-VEGF products (ocular or systemic) is restricted.

---

Official Interaction Statements

• Brolucizumab must not be administered concurrently with any other anti-VEGF medicinal product (ocular or systemic), a formal restriction noted in regulatory labels.
• The medicine is not metabolized by cytochrome P450 enzymes, which minimizes the likelihood of drug interactions mediated through this major metabolic pathway.
• No documented interactions with food, alcohol, or herbal products are present in the official regulatory labels.
• No adjustment is required for the co-administration of common medicines or in patients with mild or moderate renal or hepatic impairment, due to the minimal systemic exposure.

Connection to the Overall Interaction Profile

The regulatory documents establish that the product's official interaction profile is characterized by a single, mandatory restriction against concurrent use with other anti-VEGF products. This structure confirms that Brolucizumab is not a substrate, inhibitor, or inducer of key metabolic enzymes, limiting its interaction relevance solely to the documented constraint on co-administration with products that share the same class target.

Neutralizing the VEGF-A Growth Signal

The mechanism of Brolucizumab focuses on the molecular inhibition of Vascular Endothelial Growth Factor A ( VEGF-A). Brolucizumab, a small, single-chain Fv fragment, binds directly to and neutralizes this growth factor. This prevents VEGF-A from activating its corresponding receptors ( VEGFR-1 and VEGFR-2) on endothelial cells. This action initiates the entire suppressive cascade by blocking the key signal that promotes vascular changes.

Suppressing Pathological Vascular Leakage and Growth

By blocking VEGF-A signaling, the drug modulates the biological processes of pathological angiogenesis and vascular permeability. This interference directly suppresses the proliferation and migration of endothelial cells, halting the formation of new, fragile blood vessels (neovascularization). Furthermore, the mechanism reduces the signaling that causes existing pathological vessels to become leaky. The physiological consequence is a reduction in fluid extravasation and an anatomical change in the blood vessel network in the back of the eye.

Sustained Action and Mechanistic Constraints

The drug's small molecular size and resulting high molar concentration at the site of action contribute to the duration of VEGF pathway suppression within the local tissue. However, this unique molecular structure is also associated with a known mechanistic constraint: in rare instances, an immune-mediated intraocular inflammatory response can functionally override the intended anti-leakage action.

Administration Overview

Administration Scope	Details
Route of administration:	Intravitreal injection into the vitreous humour of the eye.
Dosing schedule:	Dose: A fixed volume of 0.05 mL containing 6 mg of brolucizumab.
	Neovascular AMD (nAMD): Loading Phase: Monthly for the first three doses. Maintenance Phase: Treatment every 8 to 12 weeks.
	Diabetic Macular Edema (DME): Loading Phase: Every six weeks for the first five doses. Maintenance Phase: Treatment every 8 to 12 weeks.
Timing in relation to meals:	Not applicable; administration is by local injection.
Preparation requirements:	The product must be visually inspected before use, and any excess volume in the container must be expelled to ensure only the accurate 0.05 mL dose is delivered.
Age-group administration rules:	Older Adults (65 years and older): No dosage adjustment is required. Safety and efficacy for the pediatric population have not been established.
Missed-dose rules:	Treatment is typically withheld and not resumed earlier than the next scheduled treatment interval if specified decreases in visual acuity occur.
Special procedural conditions:	Administration must be performed by a qualified physician experienced in intravitreal injections under aseptic conditions.

---

Instruction Classifications

Classification	Detail
Administration method type:	Local Injectable (Intravitreal)
Frequency pattern:	Phased (Fixed Loading to Flexible 8–12 Week Maintenance)
Use-context constraints:	Requires a specialist setting (aseptic conditions); intended for single-eye use per container.

---

Resulting Procedural Structure

Step sequence:

• The solution is visually inspected for appearance before use.
• The single-use container is prepared to ensure only the 0.05 mL dose is available for injection.
• The injection is administered intravitreally by a qualified physician using a controlled, aseptic technique.
• The course is initiated with a loading phase of fixed-interval injections (three or five doses, depending on the indication).
• Following the loading phase, the patient transitions to an individualized maintenance schedule of 8 to 12 weeks, based on clinical assessment.

Connection to the overall use protocol: The administration instructions establish a protocol for local delivery, confirming that the drug is given only as an injection directly into the eye at a standardized 6 mg dose. The regimen is structured into an intensive loading phase followed by a long-term maintenance phase with intervals adjusted based on disease activity, but never shorter than 8 weeks. These procedures ensure the medicine is delivered correctly under specialist oversight.

Research Evidence / Overview of Studies for Beovu

---

Evidence for Neovascular (Wet) Age-Related Macular Degeneration (nAMD)

Research for nAMD was primarily conducted through large, controlled two-year Phase 3 trials, HAWK and HARRIER. These studies monitored outcomes including changes to visual function and measurements of the macula’s anatomical structure, such as vision scores and fluid markers. Findings indicate patterns related to measured changes in participants' vision scores and described changes in anatomical markers related to fluid accumulation. Researchers also explored whether participants could be treated on an extended dosing schedule, examining the proportion of individuals who received an injection every 12 weeks after the initial doses.

---

Evidence for Diabetic Macular Edema (DME)

The evidence for DME stems from large, controlled two-year Phase 3 trials, KESTREL and KITE, involving adults with visual impairment due to DME. Research examined functional outcomes, such as changes in Best-Corrected Visual Acuity (BCVA), and anatomical outcomes, specifically changes in Central Subfield Thickness (CST), which is associated with macular swelling. Trial results describe patterns observed in the studies regarding measured changes in vision scores and described changes in the measurements of macular swelling. Researchers also examined the potential for participants to be treated on extended dosing intervals.

---

Known Research Gaps and Uncertainties

The foundational evidence for both nAMD and DME covers a follow-up duration extending up to two years in the controlled clinical trial setting. However, long-term information is not fully established beyond this period, and evidence related to the performance and durability of the extended dosing intervals in real-world settings is still emerging.

A significant area that is still being studied involves the risk of intraocular inflammation, which was associated with the medicine in both clinical trials and post-marketing reports. Additionally, data for certain groups remain insufficient, as the principal trials focused on general adult populations. The results apply only to the populations studied, and evidence is limited regarding outcomes for specific subgroups, such as those with complex pre-existing conditions.

Common questions about Beovu (FAQ)

Q: What is Beovu (brolucizumab) and how does it work?

Beovu is an injectable medicine known as an anti-VEGF therapy (Vascular Endothelial Growth Factor inhibitor). According to regulatory documents, it works by binding to and inhibiting VEGF-A, a protein that causes the growth of abnormal and leaky blood vessels in the eye. By blocking this protein, regulatory documents state that Beovu is intended to help reduce the progression of fluid and swelling in the retina.

---

Q: What eye conditions is Beovu approved to treat?

Official product information states that Beovu is approved to treat specific conditions that affect the central part of the retina, the macula. These include neovascular (wet) age-related macular degeneration (nAMD) and macular edema following Retinal Vein Occlusion (RVO). If Beovu is appropriate for your condition is a decision made by your treating doctor.

---

Q: How is Beovu administered?

Beovu is administered as an intravitreal injection, meaning the medicine is injected directly into the vitreous humor (the gel-like center) of the eye. This procedure is always performed by a qualified healthcare professional. Studies and official information indicate that this method ensures the medication reaches the site of the disease within the eye.

---

Q: How long does the effect of a Beovu injection last?

The official prescribing information indicates that after an initial treatment phase, Beovu is administered at intervals determined by your eye specialist, following a comprehensive assessment. The goal is to provide sustained therapeutic benefit by keeping the disease activity under control. The treating physician monitors the patient's eye condition to determine the appropriate treatment schedule.

Storage and Disposal of Beovu (Brolucizumab)

The specialized biologic nature of Beovu requires strict adherence to official storage and handling rules to maintain its integrity.

---

Storage Requirements

Beovu must be stored in a refrigerator between 2°C to 8°C (36°F to 46°F) and must not be frozen. To protect the solution from light, it must be kept in its original outer carton.

• Stability Limit: If removed from the refrigerator, the unopened product is stable at room temperature (20°C to 25°C) for a maximum of 24 hours before it must be discarded if unused.
• Child Safety: The medicine must be kept out of the sight and reach of children.

---

Disposal Instructions

Each vial or pre-filled syringe is for single use only. Any unused medicinal product and waste materials, including the excess solution, must be discarded in accordance with local requirements for pharmaceutical waste.